Clostridium botulinum explained

Clostridium botulinum is a gram-positive,[1] rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce botulinum toxin, which is a neurotoxin.[2] [3]

C. botulinum is a diverse group of pathogenic bacteria. Initially, they were grouped together by their ability to produce botulinum toxin and are now known as four distinct groups, C. botulinum groups I–IV. Along with some strains of Clostridium butyricum and Clostridium baratii, these bacteria all produce the toxin.[2]

Botulinum toxin can cause botulism, a severe flaccid paralytic disease in humans and other animals, and is the most potent toxin known to science, natural or synthetic, with a lethal dose of 1.3–2.1 ng/kg in humans.[4] [5]

C. botulinum is commonly associated with bulging canned food; bulging, misshapen cans can be due to an internal increase in pressure caused by gas produced by bacteria.[6]

C. botulinum is responsible for foodborne botulism (ingestion of preformed toxin), infant botulism (intestinal infection with toxin-forming C. botulinum), and wound botulism (infection of a wound with C. botulinum). C. botulinum produces heat-resistant endospores that are commonly found in soil and are able to survive under adverse conditions.[2]

Microbiology

C. botulinum is a Gram-positive, rod-shaped, spore-forming bacterium. It is an obligate anaerobe, the organism survives in an environment that lacks oxygen. However, C. botulinum tolerates traces of oxygen due to the enzyme superoxide dismutase, which is an important antioxidant defense in nearly all cells exposed to oxygen.[7] C. botulinum is able to produce the neurotoxin only during sporulation, which can happen only in an anaerobic environment.

C. botulinum is divided into four distinct phenotypic groups (I-IV) and is also classified into seven serotypes (A–G) based on the antigenicity of the botulinum toxin produced.[8] [9] On the level visible to DNA sequences, the phenotypic grouping matches the results of whole-genome and rRNA analyses, and setotype grouping approximates the result of analyses focused specifically on the toxin sequence. The two phylogenetic trees do not match because of the ability of the toxin gene cluster to be horizontally transferred.[10]

Serotypes

Botulinum neurotoxin (BoNT) production is the unifying feature of the species. Seven serotypes of toxins have been identified that are allocated a letter (A–G), several of which can cause disease in humans. They are resistant to degradation by enzymes found in the gastrointestinal tract. This allows for ingested toxins to be absorbed from the intestines into the bloodstream.[5] Toxins can be further differentiated into subtypes on the bases of smaller variations.[11] However, all types of botulinum toxin are rapidly destroyed by heating to 100 °C for 15 minutes (900 seconds). 80 °C for 30 minutes also destroys BoNT.[12] [13]

Most strains produce one type of BoNT, but strains producing multiple toxins have been described. C. botulinum producing B and F toxin types have been isolated from human botulism cases in New Mexico and California.[14] The toxin type has been designated Bf as the type B toxin was found in excess to the type F. Similarly, strains producing Ab and Af toxins have been reported.

Evidence indicates the neurotoxin genes have been the subject of horizontal gene transfer, possibly from a viral (bacteriophage) source. This theory is supported by the presence of integration sites flanking the toxin in some strains of C. botulinum. However, these integrations sites are degraded (except for the C and D types), indicating that the C. botulinum acquired the toxin genes quite far in the evolutionary past. Nevertheless, further transfers still happen via the plasmids and other mobile elements the genes are located on.[15]

Toxin types in disease

Only botulinum toxin types A, B, E, F and H (FA) cause disease in humans. Types A, B, and E are associated with food-borne illness, while type E is specifically associated with fish products. Type C produces limber-neck in birds and type D causes botulism in other mammals.[16] No disease is associated with type G.[17] The "gold standard" for determining toxin type is a mouse bioassay, but the genes for types A, B, E, and F can now be readily differentiated using quantitative PCR.[18] Type "H" is in fact a recombinant toxin from types A and F. It can be neutralized by type A antitoxin and no longer is considered a distinct type.[19]

A few strains from organisms genetically identified as other Clostridium species have caused human botulism: C. butyricum has produced type E toxin[20] and C. baratii had produced type F toxin.[21] The ability of C. botulinum to naturally transfer neurotoxin genes to other clostridia is concerning, especially in the food industry, where preservation systems are designed to destroy or inhibit only C. botulinum but not other Clostridium species.

Metabolism

Many C. botulinum genes play a role in the breakdown of essential carbohydrates and the metabolism of sugars. Chitin is the preferred source of carbon and nitrogen for C. botulinum.[22] Hall A strain of C. botulinum has an active chitinolytic system to aid in the breakdown of chitin. Type A and B of C. botulinum production of BoNT is affected by nitrogen and carbon nutrition.[23] [24] [25] There is evidence that these processes are also under catabolite repression.[26]

Groups

Physiological differences and genome sequencing at 16S rRNA level support the subdivision of the C. botulinum species into groups I-IV.[27] Some authors have briefly used groups V and VI, corresponding to toxin-producing C. baratii and C. butyricum. What used to be group IV is now C. argentinense.

Phenotypic groups of toxin-producing Clostridium! Property! Group I! Group II! Group III! C. argentinense! C. baratii! C. butyricum
Proteolysis (casein)
Saccharolysis
Lipase
Toxin TypesA, B, FB, E, FC, DGFE
Toxin genechromosome/plasmidchromosome/plasmidbacteriophageplasmidchromosome[28] chromosome[29]
Close relatives
  • C. beijerinckii
  • C. butyricum
 N/A (already a species)

Although group II cannot degrade native protein such as casein, coagulated egg white, and cooked meat particles, it is able to degrade gelatin.

Human botulism is predominantly caused by group I or II C. botulinum.[30] Group III organisms mainly cause diseases in non-human animals.[30]

Laboratory isolation

In the laboratory, C. botulinum is usually isolated in tryptose sulfite cycloserine (TSC) growth medium in an anaerobic environment with less than 2% oxygen. This can be achieved by several commercial kits that use a chemical reaction to replace O2 with CO2. C. botulinum (groups I through III) is a lipase-positive microorganism that grows between pH of 4.8 and 7.0 and cannot use lactose as a primary carbon source, characteristics important for biochemical identification.[31]

Transmission and sporulation

The exact mechanism behind sporulation of C. botulinum is not known. Different strains of C. botulinum can be divided into three different groups, group I, II, and III, based on environmental conditions like heat resistance, temperature, and biome.[32] Within each group, different strains will use different strategies to adapt to their environment to survive. Unlike other clostridial species, C. botulinum spores will sporulate as it enters the stationary phase.[33] C. botulinum relies on quorum-sensing to initiate the sporulation process. C. botulinum spores are not found in human feces unless the individual has contracted botulism,[34] but C. botulinum cannot spread from person to person.[35]

Motility structures

The most common motility structure for C. botulinum is a flagellum. Though this structure is not found in all strains of C. botulinum, most produce peritrichous flagella.[36] When comparing the different strains, there is also differences in the length of the flagella and how many are present on the cell.

Growth conditions and prevention

C. botulinum is a soil bacterium. The spores can survive in most environments and are very hard to kill. They can survive the temperature of boiling water at sea level, thus many foods are canned with a pressurized boil that achieves even higher temperatures, sufficient to kill the spores.[37] [38] This bacteria is widely distributed in nature and can be assumed to be present on all food surfaces. Its optimum growth temperature is within the mesophilic range. In spore form, it is a heat resistant pathogen that can survive in low acid foods and grow to produce toxins. The toxin attacks the nervous system and will kill an adult at a dose of around 75 ng.[39] Botulinum toxin can be destroyed by holding food at 100 °C for 10 minutes; however, because of its potency, this is not recommended by the USA's FDA as a means of control.[40]

Botulism poisoning can occur due to preserved or home-canned, low-acid food that was not processed using correct preservation times and/or pressure.[41] Growth of the bacterium can be prevented by high acidity, high ratio of dissolved sugar, high levels of oxygen, very low levels of moisture, or storage at temperatures below 3 °C (38 °F) for type A. For example, in a low-acid, canned vegetable such as green beans that are not heated enough to kill the spores (i.e., a pressurized environment) may provide an oxygen-free medium for the spores to grow and produce the toxin. However, pickles are sufficiently acidic to prevent growth;[42] even if the spores are present, they pose no danger to the consumer.

Honey, corn syrup, and other sweeteners may contain spores, but the spores cannot grow in a highly concentrated sugar solution; however, when a sweetener is diluted in the low-oxygen, low-acid digestive system of an infant, the spores can grow and produce toxin. As soon as infants begin eating solid food, the digestive juices become too acidic for the bacterium to grow.[43]

The control of food-borne botulism caused by C. botulinum is based almost entirely on thermal destruction (heating) of the spores or inhibiting spore germination into bacteria and allowing cells to grow and produce toxins in foods. Conditions conducive of growth are dependent on various environmental factors.Growth of C. botulinum is a risk in low acid foods as defined by having a pH above 4.6[44] although growth is significantly retarded for pH below 4.9.[45]

Taxonomic history

Taxid:726
Ploidy:haploid
Chromosomes:2 (1 plasmid)
Size:3.91 Mb
Year:2007

C. botulinum was first recognized and isolated in 1895 by Emile van Ermengem from home-cured ham implicated in a botulism outbreak.[46] The isolate was originally named Bacillus botulinus, after the Latin word for sausage, botulus. ("Sausage poisoning" was a common problem in 18th- and 19th-century Germany, and was most likely caused by botulism.)[47] However, isolates from subsequent outbreaks were always found to be anaerobic spore formers, so Ida A. Bengtson proposed that both be placed into the genus Clostridium, as the genus Bacillus was restricted to aerobic spore-forming rods.[48]

Since 1959, all species producing the botulinum neurotoxins (types A–G) have been designated C. botulinum. Substantial phenotypic and genotypic evidence exists to demonstrate heterogeneity within the species, with at least four clearly-defined "groups" (see) straddling other species, implying that they each deserve to be a genospecies.[49] [50]

The situation as of 2018 is as follows:[50]

Smith et al. (2018) argues that group I should be called C. parabotulinum and group III be called C. novyi sensu lato, leaving only group II in C. botulinum. This argument is not accepted by the LPSN and would cause an unjustified change of the type strain under the Prokaryotic Code.[50] Dobritsa et al. (2018) argues, without formal descriptions, that group II can potentially be made into two new species.[55]

The complete genome of C. botulinum ATCC 3502 has been sequenced at Wellcome Trust Sanger Institute in 2007. This strain encodes a type "A" toxin.[56]

Diagnosis

Physicians may consider the diagnosis of botulism based on a patient's clinical presentation, which classically includes an acute onset of bilateral cranial neuropathies and symmetric descending weakness.[57] [58] Other key features of botulism include an absence of fever, symmetric neurologic deficits, normal or slow heart rate and normal blood pressure, and no sensory deficits except for blurred vision.[59] [60] A careful history and physical examination is paramount to diagnose the type of botulism, as well as to rule out other conditions with similar findings, such as Guillain–Barré syndrome, stroke, and myasthenia gravis.[61] Depending on the type of botulism considered, different tests for diagnosis may be indicated.

Other tests that may be helpful in ruling out other conditions are:

Pathology

Foodborne botulism

Signs and symptoms of foodborne botulism typically begin between 18 and 36 hours after the toxin gets into your body, but can range from a few hours to several days, depending on the amount of toxin ingested. Symptoms include:[69] [70]

Wound botulism

Most people who develop wound botulism inject drugs several times a day, so determining a timeline of when onset symptoms first occurred and when the toxin entered the body can be difficult. It is more common in people who inject black tar heroin.[71] Wound botulism signs and symptoms include:[72]

Infant botulism

If infant botulism is related to food, such as honey, problems generally begin within 18 to 36 hours after the toxin enters the baby's body. Signs and symptoms include:

Beneficial effects of botulinum toxin

Purified botulinum toxin is diluted by a physician for treatment of:[73]

Adult intestinal toxemia

A very rare form of botulism that occurs by the same route as infant botulism but is among adults. Occurs rarely and sporadically. Signs and symptoms include:[75]

Treatment

In the case of a diagnosis or suspicion of botulism, patients should be hospitalized immediately, even if the diagnosis and/or tests are pending. Additionally if botulism is suspected, patients should be treated immediately with antitoxin therapy in order to reduce mortality. Immediate intubation is also highly recommended, as respiratory failure is the primary cause of death from botulism.[77] [78] [79]

In North America, an equine-derived heptavalent botulinum antitoxin is used to treat all serotypes of non-infant naturally occurring botulism. For infants less than one year of age, botulism immune globulin is used to treat type A or type B.[80] [81]

Outcomes vary between one and three months, but with prompt interventions, mortality from botulism ranges from less than 5 percent to 8 percent.[82]

Vaccination

There used to be a formalin-treated toxoid vaccine against botulism (serotypes A-E), but it was discontinued in 2011 due to declining potency in the toxoid stock. It was originally intended for people at risk of exposure. A few new vaccines are under development.[83]

Use and detection

C. botulinum is used to prepare the medicaments Botox, Dysport, Xeomin, and Neurobloc used to selectively paralyze muscles to temporarily relieve muscle function. It has other "off-label" medical purposes, such as treating severe facial pain, such as that caused by trigeminal neuralgia.[84]

Botulinum toxin produced by C. botulinum is often believed to be a potential bioweapon as it is so potent that it takes about 75 nanograms to kill a person (of 1 ng/kg, assuming an average person weighs ~75 kg); 1 kilogram of it would be enough to kill the entire human population.

A "mouse protection" or "mouse bioassay" test determines the type of C. botulinum toxin present using monoclonal antibodies. An enzyme-linked immunosorbent assay (ELISA) with digoxigenin-labeled antibodies can also be used to detect the toxin,[85] and quantitative PCR can detect the toxin genes in the organism.

C. botulinum in different geographical locations

A number of quantitative surveys for C. botulinum spores in the environment have suggested a prevalence of specific toxin types in given geographic areas, which remain unexplained.

!Location!
North AmericaType A C. botulinum predominates the soil samples from the western regions, while type B is the major type found in eastern areas.[86] The type-B organisms were of the proteolytic type I. Sediments from the Great Lakes region were surveyed after outbreaks of botulism among commercially reared fish, and only type E spores were detected.[87] [88] [89] In a survey, type-A strains were isolated from soils that were neutral to alkaline(average pH 7.5), while type-B strains were isolated from slightly acidic soils (average pH 6.23).
EuropeC. botulinum type E is prevalent in aquatic sediments in Norway and Sweden,[90] Denmark,[91] the Netherlands, the Baltic coast of Poland, and Russia. The type-E C. botulinum was suggested to be a true aquatic organism, which was indicated by the correlation between the level of type-E contamination and flooding of the land with seawater. As the land dried, the level of type E decreased and type B became dominant [92] In soil and sediment from the United Kingdom, C. botulinum type B predominates. In general, the incidence is usually lower in soil than in sediment. In Italy, a survey conducted in the vicinity of Rome found a low level of contamination; all strains were proteolytic C. botulinum types A or B.[93]
AustraliaC. botulinum type A was found to be present in soil samples from mountain areas of Victoria.[94] Type-B organisms were detected in marine mud from Tasmania.[95] Type-A C. botulinum has been found in Sydney suburbs and types A and B were isolated from urban areas. In a well-defined area of the Darling-Downs region of Queensland, a study showed the prevalence and persistence of C. botulinum type B after many cases of botulism in horses.

Further reading

Notes and References

  1. Book: Tiwari A, Nagalli S . Clostridium Botulinum . 2021. http://www.ncbi.nlm.nih.gov/books/NBK553081/. StatPearls. Treasure Island (FL). StatPearls Publishing. 31971722. 2021-09-23.
  2. Peck MW . Biology and genomic analysis of Clostridium botulinum . Advances in Microbial Physiology . 55 . 183–265, 320 . 2009 . 19573697 . 10.1016/S0065-2911(09)05503-9 . 978-0-12-374790-7 .
  3. Lindström M, Korkeala H . Laboratory diagnostics of botulism . Clinical Microbiology Reviews . 19 . 2 . 298–314 . April 2006 . 16614251 . 1471988 . 10.1128/cmr.19.2.298-314.2006 .
  4. Košenina S, Masuyer G, Zhang S, Dong M, Stenmark P . Crystal structure of the catalytic domain of the Weissella oryzae botulinum-like toxin . FEBS Letters . 593 . 12 . 1403–1410 . June 2019 . 31111466 . 10.1002/1873-3468.13446 . free .
  5. (2010). Chapter 19. Clostridium, Peptostreptococcus, Bacteroides, and Other Anaerobes. In Ryan K.J., Ray C (Eds), Sherris Medical Microbiology, 5th ed.
  6. Web site: Schneider KR, Silverberg R, Chang A, Goodrich Schneider RM . Preventing Foodborne Illness: Clostridium botulinum. edis.ifas.ufl.edu. University of Florida IFAS Extension. 7 February 2017. en. 9 January 2015.
  7. Book: Doyle MP . Food Microbiology: Fundamentals and Frontiers . ASM Press. 2007 . 978-1-55581-208-9.
  8. Peck MW, Stringer SC, Carter AT . Clostridium botulinum in the post-genomic era . Food Microbiology . 28 . 2 . 183–191 . April 2011 . 21315972 . 10.1016/j.fm.2010.03.005 .
  9. Shukla HD, Sharma SK . Clostridium botulinum: a bug with beauty and weapon . Critical Reviews in Microbiology . 31 . 1 . 11–18 . 2005 . 15839401 . 10.1080/10408410590912952 . 2855356 .
  10. Book: Hill KK, Smith TJ . Genetic Diversity Within Clostridium botulinum Serotypes, Botulinum Neurotoxin Gene Clusters and Toxin Subtypes . Botulinum Neurotoxins . Current Topics in Microbiology and Immunology . 2012 . 364 . 1–20 . 10.1007/978-3-642-33570-9_1. 23239346 . 978-3-642-33569-3 .
  11. Peck MW, Smith TJ, Anniballi F, Austin JW, Bano L, Bradshaw M, Cuervo P, Cheng LW, Derman Y, Dorner BG, Fisher A, Hill KK, Kalb SR, Korkeala H, Lindström M, Lista F, Lúquez C, Mazuet C, Pirazzini M, Popoff MR, Rossetto O, Rummel A, Sesardic D, Singh BR, Stringer SC . Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature . Toxins . 9 . 1 . 38 . January 2017 . 28106761 . 5308270 . 10.3390/toxins9010038 . free .
  12. 10.1007/BF00395840 . Notermans S, Havellar AH . 1980 . Removal and inactivation of botulinum toxin during production of drinking water from surface water . Antonie van Leeuwenhoek . 46 . 5. 511–514 . 21102990.
  13. Montecucco C, Molgó J . Botulinal neurotoxins: revival of an old killer . Current Opinion in Pharmacology . 5 . 3 . 274–279 . June 2005 . 15907915 . 10.1016/j.coph.2004.12.006 .
  14. Hatheway CL, McCroskey LM . Examination of feces and serum for diagnosis of infant botulism in 336 patients . Journal of Clinical Microbiology . 25 . 12 . 2334–2338 . December 1987 . 3323228 . 269483 . 10.1128/JCM.25.12.2334-2338.1987 .
  15. Poulain B, Popoff MR . Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic? . Toxins . 11 . 1 . 34 . January 2019 . 30641949 . 6357194 . 10.3390/toxins11010034 . free .
  16. Meurens F, Carlin F, Federighi M, Filippitzi ME, Fournier M, Fravalo P, Ganière JP, Grisot L, Guillier L, Hilaire D, Kooh P, Le Bouquin-Leneveu S, Le Maréchal C, Mazuet C, Morvan H, Petit K, Vaillancourt JP, Woudstra C . Clostridium botulinum type C, D, C/D, and D/C: An update . Frontiers in Microbiology . 13 . 1099184 . 2023-01-05 . 36687640 . 9849819 . 10.3389/fmicb.2022.1099184 . free .
  17. (2013). Chapter 11. Spore-Forming Gram-Positive Bacilli: Bacillus and Clostridium Species. In Brooks G.F., Carroll K.C., Butel J.S., Morse S.A., Mietzner T.A. (Eds), Jawetz, Melnick, & Adelberg's Medical Microbiology, 26th ed.
  18. Satterfield BA, Stewart AF, Lew CS, Pickett DO, Cohen MN, Moore EA, Luedtke PF, O'Neill KL, Robison RA . A quadruplex real-time PCR assay for rapid detection and differentiation of the Clostridium botulinum toxin genes A, B, E and F . Journal of Medical Microbiology . 59 . Pt 1 . 55–64 . January 2010 . 19779029 . 10.1099/jmm.0.012567-0 . free .
  19. Maslanka SE, Lúquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, Raphael BH, Kalb SR, Barr JR, Rao A, Johnson EA . A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin . The Journal of Infectious Diseases . 213 . 3 . 379–385 . February 2016 . 26068781 . 4704661 . 10.1093/infdis/jiv327 .
  20. Aureli P, Fenicia L, Pasolini B, Gianfranceschi M, McCroskey LM, Hatheway CL . Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy . The Journal of Infectious Diseases . 154 . 2 . 207–211 . August 1986 . 3722863 . 10.1093/infdis/154.2.207 .
  21. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL . Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism . Journal of Clinical Microbiology . 21 . 4 . 654–655 . April 1985 . 3988908 . 271744 . 10.1128/JCM.21.4.654-655.1985 .
  22. Sebaihia M, Peck MW, Minton NP, Thomson NR, Holden MT, Mitchell WJ, Carter AT, Bentley SD, Mason DR, Crossman L, Paul CJ, Ivens A, Wells-Bennik MH, Davis IJ, Cerdeño-Tárraga AM, Churcher C, Quail MA, Chillingworth T, Feltwell T, Fraser A, Goodhead I, Hance Z, Jagels K, Larke N, Maddison M, Moule S, Mungall K, Norbertczak H, Rabbinowitsch E, Sanders M, Simmonds M, White B, Whithead S, Parkhill J . Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes . Genome Research . 17 . 7 . 1082–1092 . July 2007 . 17519437 . 1899119 . 10.1101/gr.6282807 .
  23. Leyer GJ, Johnson EA . Repression of toxin production by tryptophan in Clostridium botulinum type E . Archives of Microbiology . 154 . 5 . 443–447 . October 1990 . 2256780 . 10.1007/BF00245225 . 1990ArMic.154..443L .
  24. Patterson-Curtis SI, Johnson EA . Regulation of neurotoxin and protease formation in Clostridium botulinum Okra B and Hall A by arginine . Applied and Environmental Microbiology . 55 . 6 . 1544–1548 . June 1989 . 2669631 . 202901 . 10.1128/aem.55.6.1544-1548.1989 . 1989ApEnM..55.1544P .
  25. Schantz EJ, Johnson EA . 1992 . Properties and use of botulinum toxin and other microbial neurotoxins in medicine. . Microbiological Reviews . en . 56 . 1 . 80–99 . 10.1128/MMBR.56.1.80-99.1992 . 1579114 . 372855 . 0146-0749.
  26. Johnson EA, Bradshaw M . Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective . Toxicon . 39 . 11 . 1703–1722 . November 2001 . 11595633 . 10.1016/S0041-0101(01)00157-X . 2001Txcn...39.1703J .
  27. Book: Clostridium . Clostridium | Occurrence of Clostridium botulinum . January 1, 2003 . 10.1016/B0-12-227055-X/00255-8 . https://www.sciencedirect.com/science/article/pii/B012227055X002558 . February 19, 2021 . 1407–1413. Academic Press . 978-0-12-227055-0 . Austin JW .
  28. Mazuet C, Legeay C, Sautereau J, Bouchier C, Criscuolo A, Bouvet P, Trehard H, Jourdan Da Silva N, Popoff M . Characterization of Clostridium Baratii Type F Strains Responsible for an Outbreak of Botulism Linked to Beef Meat Consumption in France . PLOS Currents . 9 . February 2017 . 29862134 . 5959735 . 10.1371/currents.outbreaks.6ed2fe754b58a5c42d0c33d586ffc606 . 31 January 2024 . free .
  29. Hill KK, Xie G, Foley BT, Smith TJ, Munk AC, Bruce D, Smith LA, Brettin TS, Detter JC . Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains . BMC Biology . 7 . 1 . 66 . October 2009 . 19804621 . 2764570 . 10.1186/1741-7007-7-66 . free .
  30. Carter AT, Peck MW . Genomes, neurotoxins and biology of Clostridium botulinum Group I and Group II . Research in Microbiology . 166 . 4 . 303–317 . May 2015 . 25445012 . 4430135 . 10.1016/j.resmic.2014.10.010 . free .
  31. Book: Brock Biology of Microorganisms. 11th. Madigan MT, Martinko JM . Prentice Hall. 2005. 978-0-13-144329-7.
  32. Portinha IM, Douillard FP, Korkeala H, Lindström M . Sporulation Strategies and Potential Role of the Exosporium in Survival and Persistence of Clostridium botulinum . International Journal of Molecular Sciences . 23 . 2 . 754 . January 2022 . 35054941 . 8775613 . 10.3390/ijms23020754 . free . >
  33. Shen A, Edwards AN, Sarker MR, Paredes-Sabja D . Sporulation and Germination in Clostridial Pathogens . Microbiology Spectrum . 7 . 6 . November 2019 . 31858953 . 6927485 . 10.1128/microbiolspec.GPP3-0017-2018 . Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Braunstein M, Rood JI .
  34. Coproexamination for Botulinal Toxin and Clostridium botulinum . 2024-04-11 . JAMA . 1977 . 10.1001/jama.1977.03280180033021 . Dowell VR . 238 . 17 . 1829 .
  35. Web site: Botulism . 2024-04-16 . www.who.int . en.
  36. Paul . Catherine J. . Twine . Susan M. . Tam . Kevin J. . Mullen . James A. . Kelly . John F. . Austin . John W. . Logan . Susan M. . May 2007 . Flagellin Diversity in Clostridium botulinum Groups I and II: a New Strategy for Strain Identification . Applied and Environmental Microbiology . en . 73 . 9 . 2963–2975 . 10.1128/AEM.02623-06 . 0099-2240 . 1892883 . 17351097. 2007ApEnM..73.2963P .
  37. Web site: 2019-06-06 . Prevent Botulism . 2023-04-23 . Centers for Disease Control and Prevention (CDC) . en-us.
  38. Web site: Botulism: take care when canning low-acid foods . 2023-04-23 . extension.umn.edu . en.
  39. Book: Biological Safety: principles and practices . Fleming DO . ASM Press . 2000 . 267.
  40. Web site: Chapter 13: Clostridium botulinum Toxin Formation . live . https://web.archive.org/web/20210208183813/https://www.fda.gov/files/food/published/Fish-and-Fishery-Products-Hazards-and-Controls-Guidance-Chapter-13-Download.pdf . 2021-02-08 . 18 March 2022 . Fda.gov.
  41. Web site: Home Canning and Botulism . 14 April 2021 . Centers for Disease Control and Prevention.
  42. Ito KA, Chen JK, Lerke PA, Seeger ML, Unverferth JA . Effect of acid and salt concentration in fresh-pack pickles on the growth of Clostridium botulinum spores . Applied and Environmental Microbiology . 32 . 1 . 121–124 . July 1976 . 9898 . 170016 . 10.1128/aem.32.1.121-124.1976 . 1976ApEnM..32..121I .
  43. Web site: Botulism . 5 July 2021 . The Lecturio Medical Concept Library.
  44. Web site: Guidance for Commercial Processors of Acidified & Low-Acid Canned Foods . 8 October 2016 . U.S. Food and Drug Administration.
  45. Odlaug TE, Pflug IJ . Clostridium botulinum growth and toxin production in tomato juice containing Aspergillus gracilis . Applied and Environmental Microbiology . 37 . 3 . 496–504 . March 1979 . 36843 . 243244 . 10.1128/aem.37.3.496-504.1979 . 1979ApEnM..37..496O .
  46. van Ergmengem E . 1897 . Über einen neuen anaeroben Bacillus und seine Beziehungen Zum Botulismus . Zeitschrift für Hygiene und Infektionskrankheiten . 26 . 1–8.
  47. Erbguth FJ . Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin . Movement Disorders . 19 . Suppl 8 . S2–S6 . March 2004 . 15027048 . 10.1002/mds.20003 . 8190807 .
  48. Bengston IA . 1924 . Studies on organisms concerned as causative factors in botulism . Bulletin (Hygienic Laboratory (U.S.)) . 136 . 101 fv.
  49. Book: Taxonomic Relationships among the Clostridia . Uzal FA, Songer JG, Prescott JF, Popoff MR . Clostridial Diseases of Animals . 21 June 2016 . 1–5 . 10.1002/9781118728291.ch1. 978-1-118-72829-1.
  50. Smith T, Williamson CH, Hill K, Sahl J, Keim P . Botulinum Neurotoxin-Producing Bacteria. Isn't It Time that We Called a Species a Species? . mBio . 9 . 5 . September 2018 . 30254123 . 6156192 . 10.1128/mbio.01469-18 .
  51. Suen JC, Hatheway CL, Steigerwalt AG, Brenner DJ . 1988 . Clostridium argentinense sp.nov.: a genetically homogeneous group composed of all strains of Clostridium botulinum type G and some nonttoxigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme . International Journal of Systematic Bacteriology . 38 . 375–381 . 10.1099/00207713-38-4-375 . free.
  52. Rejection of Clostridium putrificum and conservation of Clostridium botulinum and Clostridium sporogenes-Opinion 69. Judicial Commission of the International Committee on Systematic Bacteriology . International Journal of Systematic Bacteriology . 49 Pt 1 . 1 . 339 . January 1999 . 10028279 . 10.1099/00207713-49-1-339 . free .
  53. Web site: Species: Clostridium combesii . lpsn.dsmz.de . en.
  54. Arahal DR, Busse HJ, Bull CT, Christensen H, Chuvochina M, Dedysh SN, Fournier PE, Konstantinidis KT, Parker CT, Rossello-Mora R, Ventosa A, Göker M . Judicial Opinions 112-122 . International Journal of Systematic and Evolutionary Microbiology . 72 . 8 . August 2022 . 35947640 . 10.1099/ijsem.0.005481 . 251470203 .
  55. Dobritsa AP, Kutumbaka KK, Samadpour M . Reclassification of Eubacterium combesii and discrepancies in the nomenclature of botulinum neurotoxin-producing clostridia: Challenging Opinion 69. Request for an Opinion . International Journal of Systematic and Evolutionary Microbiology . 68 . 9 . 3068–3075 . September 2018 . 30058996 . 10.1099/ijsem.0.002942 . free .
  56. Web site: Clostridium botulinum A str. ATCC 3502 genome assembly ASM6358v1 . NCBI . en.
  57. Cherington M . Clinical spectrum of botulism . Muscle & Nerve . 21 . 6 . 701–710 . June 1998 . 9585323 . 10.1002/(sici)1097-4598(199806)21:6<701::aid-mus1>3.0.co;2-b .
  58. Cai S, Singh BR, Sharma S . Botulism diagnostics: from clinical symptoms to in vitro assays . Critical Reviews in Microbiology . 33 . 2 . 109–125 . April 2007 . 17558660 . 10.1080/10408410701364562 . 23470999 .
  59. Web site: Diagnosis and Treatment Botulism . 2017-10-08 . CDC . en-us.
  60. News: Botulism: Rare but serious food poisoning . 2017-11-18 . Mayo Clinic . en.
  61. Rao AK, Sobel J, Chatham-Stephens K, Luquez C . Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 . en-us . MMWR. Recommendations and Reports . 70 . 2 . 1–30 . May 2021 . 33956777 . 8112830 . 10.15585/mmwr.rr7002a1 .
  62. Lindström M, Korkeala H . Laboratory diagnostics of botulism . Clinical Microbiology Reviews . 19 . 2 . 298–314 . April 2006 . 16614251 . 1471988 . 10.1128/CMR.19.2.298-314.2006 .
  63. Akbulut D, Grant KA, McLauchlin J . Improvement in laboratory diagnosis of wound botulism and tetanus among injecting illicit-drug users by use of real-time PCR assays for neurotoxin gene fragments . Journal of Clinical Microbiology . 43 . 9 . 4342–4348 . September 2005 . 16145075 . 1234055 . 10.1128/JCM.43.9.4342-4348.2005 .
  64. Dezfulian M, McCroskey LM, Hatheway CL, Dowell VR . Selective medium for isolation of Clostridium botulinum from human feces . Journal of Clinical Microbiology . 13 . 3 . 526–531 . March 1981 . 7016901 . 273826 . 10.1128/JCM.13.3.526-531.1981 .
  65. Antonucci L, Locci C, Schettini L, Clemente MG, Antonucci R . Infant botulism: an underestimated threat . Infectious Diseases . 53 . 9 . 647–660 . September 2021 . 33966588 . 10.1080/23744235.2021.1919753 .
  66. O'Suilleabhain P, Low PA, Lennon VA . Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates . Neurology . 50 . 1 . 88–93 . January 1998 . 9443463 . 10.1212/wnl.50.1.88 . 39437882 .
  67. Mechem CC, Walter FG . Wound botulism . Veterinary and Human Toxicology . 36 . 3 . 233–237 . June 1994 . 8066973 .
  68. Taraschenko OD, Powers KM . Neurotoxin-induced paralysis: a case of tick paralysis in a 2-year-old child . Pediatric Neurology . 50 . 6 . 605–607 . June 2014 . 24679414 . 10.1016/j.pediatrneurol.2014.01.041 .
  69. Lonati D, Schicchi A, Crevani M, Buscaglia E, Scaravaggi G, Maida F, Cirronis M, Petrolini VM, Locatelli CA . Foodborne Botulism: Clinical Diagnosis and Medical Treatment . Toxins . 12 . 8 . 509 . August 2020 . 32784744 . 7472133 . 10.3390/toxins12080509 . free .
  70. Web site: June 13, 2015 . Botulism Symptoms . January 25, 2016 . Mayo Clinic.
  71. Web site: 2022-05-31 . Injection Drug Use and Wound Botulism Botulism CDC . 2024-04-17 . www.cdc.gov . en-us.
  72. Schulte M, Hamsen U, Schildhauer TA, Ramczykowski T . Effective and rapid treatment of wound botulism, a case report . BMC Surgery . 17 . 1 . 103 . October 2017 . 29073888 . 5658925 . 10.1186/s12893-017-0300-4 . free .
  73. Chiu SY, Patel B, Burns MR, Legacy J, Shukla AW, Ramirez-Zamora A, Deeb W, Malaty IA . 2020-02-27 . High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy . Tremor and Other Hyperkinetic Movements . 10 . 10.5334/tohm.527 . free . 2160-8288.
  74. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K . Botulinum toxin as a biological weapon: medical and public health management . JAMA . 285 . 8 . 1059–1070 . February 2001 . 11209178 . 10.1001/jama.285.8.1059 .
  75. Harris RA, Anniballi F, Austin JW . Adult Intestinal Toxemia Botulism . Toxins . 12 . 2 . 81 . January 2020 . 31991691 . 7076759 . 10.3390/toxins12020081 . free .
  76. Web site: Botulism . Centers for Disease Control and Prevention . 23 October 2016 .
  77. Witoonpanich R, Vichayanrat E, Tantisiriwit K, Wongtanate M, Sucharitchan N, Oranrigsupak P, Chuesuwan A, Nakarawat W, Tima A, Suwatcharangkoon S, Ingsathit A, Rattanasiri S, Wananukul W . Survival analysis for respiratory failure in patients with food-borne botulism . Clinical Toxicology . 48 . 3 . 177–183 . March 2010 . 20184431 . 10.3109/15563651003596113 . 23108891 .
  78. Sandrock CE, Murin S . Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism . Chest . 120 . 2 . 562–566 . August 2001 . 11502659 . 10.1378/chest.120.2.562 .
  79. Wongtanate M, Sucharitchan N, Tantisiriwit K, Oranrigsupak P, Chuesuwan A, Toykeaw S, Suputtamongkol Y . Signs and symptoms predictive of respiratory failure in patients with foodborne botulism in Thailand . The American Journal of Tropical Medicine and Hygiene . 77 . 2 . 386–389 . August 2007 . 17690419 . 10.4269/ajtmh.2007.77.386 . free .
  80. Web site: Health Canada . 2012-07-18 . Botulism - Guide for Healthcare Professionals . 2023-11-01 .
  81. Web site: Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E . 2023-11-01 . www.cdc.gov.
  82. Varma JK, Katsitadze G, Moiscrafishvili M, Zardiashvili T, Chokheli M, Tarkhashvili N, Jhorjholiani E, Chubinidze M, Kukhalashvili T, Khmaladze I, Chakvetadze N, Imnadze P, Hoekstra M, Sobel J . Signs and symptoms predictive of death in patients with foodborne botulism--Republic of Georgia, 1980-2002 . Clinical Infectious Diseases . 39 . 3 . 357–362 . August 2004 . 15307002 . 10.1086/422318 . 20675701 .
  83. Sundeen G, Barbieri JT . Vaccines against Botulism . Toxins . 9 . 9 . 268 . September 2017 . 28869493 . 5618201 . 10.3390/toxins9090268 . free .
  84. Guardiani E, Sadoughi B, Blitzer A, Sirois D . A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A . The Laryngoscope . 124 . 2 . 413–417 . February 2014 . 23818108 . 10.1002/lary.24286 .
  85. Sharma SK, Ferreira JL, Eblen BS, Whiting RC . Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies . Applied and Environmental Microbiology . 72 . 2 . 1231–1238 . February 2006 . 16461671 . 1392902 . 10.1128/AEM.72.2.1231-1238.2006 . 2006ApEnM..72.1231S . free .
  86. Book: Hauschild AH . 1989 . Clostridium botulinum. . Doyle MP . Food-borne Bacterial Pathogens. . Marcel Dekker . New York . 111–189 .
  87. Bott TL, Johnson J, Foster EM, Sugiyama H . Possible origin of the high incidence of Clostridium botulinum type E in an inland bay (Green Bay of Lake Michigan) . Journal of Bacteriology . 95 . 5 . 1542–7 . May 1968 . 4870273 . 252172 . 10.1128/jb.95.5.1542-1547.1968 .
  88. Eklund MW, Peterson ME, Poysky FT, Peck LW, Conrad JF . Botulism in juvenile coho salmon (Oncorhynchus kisutch) in the United States. . Aquaculture . February 1982 . 27 . 1 . 1–11 . 10.1016/0044-8486(82)90104-1 . 1982Aquac..27....1E .
  89. Eklund MW, Poysky FT, Peterson ME, Peck LW, Brunson WD . Type E botulism in salmonids and conditions contributing to outbreaks. . Aquaculture . October 1984 . 41 . 4 . 293–309 . 10.1016/0044-8486(84)90198-4 . 1984Aquac..41..293E .
  90. Johannsen A . Clostridium botulinum in Sweden and the adjacent waters. . Journal of Applied Bacteriology . April 1963 . 26 . 1 . 43–47 . 10.1111/j.1365-2672.1963.tb01153.x .
  91. Huss HH . Distribution of Clostridium botulinum . Applied and Environmental Microbiology . 39 . 4 . 764–9 . April 1980 . 6990867 . 291416 . 10.1128/aem.39.4.764-769.1980 . 1980ApEnM..39..764H .
  92. Portinha IM, Douillard FP, Korkeala H, Lindström M . Sporulation Strategies and Potential Role of the Exosporium in Survival and Persistence of Clostridium botulinum . International Journal of Molecular Sciences . 23 . 2 . 754 . January 2022 . 35054941 . 8775613 . 10.3390/ijms23020754 . free .
  93. Creti R, Fenicia J, Aureli P . May 1990 . Occurrence of Clostridium botulinum in the soil of the vicinity of Rome . Current Microbiology . 20 . 5 . 317–321 . 10.1007/bf02091912.
  94. Eales CE, Gillespie JM . The isolation of Clostridium botulinum type A from Victorian soils . The Australian Journal of Science . 10 . 1 . 20 . August 1947 . 20267540 .
  95. Ohye DF, Scott WJ . 1957 . Studies in the physiology of Clostridium botulinum type E . Australian Journal of Biological Sciences . 10 . 85–94 . 10.1071/BI9570085.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Clostridium botulinum".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.